摘要
目的研究AKT2及磷酸化AKT2(p-AKT2)在非小细胞肺癌(NSCLC)组织中的表达及临床意义。方法应用免疫组织化学法检测137例非小细胞肺癌组织中AKT2和p-AKT2表达,分析AKT2及p-AKT2表达与肺癌预后的关系。结果非小细胞肺癌组织中AKT2在腺癌及鳞癌组织中的阳性表达率分别为60.5%和54.1%,差异无统计学意义(P>0.05);p-AKT2在腺癌及鳞癌组织中的阳性表达率分别为68.4%和47.5%,差异有统计学意义(P<0.05)。同时,本研究发现AKT2和p-AKT2的表达在患者的年龄、性别、肿瘤TNM分期及细胞分化程度等方面差异无统计学意义(P>0.05)。生存分析显示,AKT2表达阳性的NSCLC患者5年生存率及中位生存时间与阴性表达者比较差异无统计学意义〔36%vs.30%,(33.960±2.485)月vs.(31.338±2.868)月,P>0.05〕;而p-AKT2表达阳性的患者5年生存率及中位生存时间与阴性表达者比较差异有统计学意义〔20%vs.56%,(28.464±2.235)月vs.(39.214±3.075)月,P<0.05〕。进一步分层分析发现,Ⅰ期NSCLC患者中,AKT2表达阳性者5年中位生存时间与阴性表达者比较差异无统计学意义〔(34.778±4.469)月vs.(40.133±5.632)月,P>0.05〕;而p-AKT2表达阳性的NSCLC患者5年中位生存时间与阴性表达者比较差异有统计学意义〔(29.808±4.337)月vs.(47.875±4.852)月,P<0.05〕。结论 p-AKT2在肺腺癌中的表达高于肺鳞癌,且p-AKT2的阳性表达缩短了NSCLC患者的5年中位生存时间。
Objective To study the expression and clinical significance of AKT2,phosphorylated AKT2(p-AKT2) in non-small cell lung cancer(NSCLC).Methods The tumor tissues were obtained from 137 cases of NSCLC,the expressions of AKT2 and p-AKT2 in the tissues were measured by immunohistochemistry.The statistic analysis was carried on to study the correlation of AKT2,p-AKT2 expression to the type of lung cancer,TNM stage,pathological grading.Survival analysis was also studied.Results The positive rates of AKT2 in lung adenocarcinoma and squamous carcinoma were 60.5% and 54.1% respectively(P>0.05).While the positive rates of p-AKT2 in lung adenocarcinoma and squamous carcinoma were 68.4% and 47.5%(P<0.05).The expressions of AKT2 and p-AKT2 were not correlated with age,gender,TNM stage and cell differentiation degree.Further more,survival analysis revealed that 5-year survival rate and median survival time for the patients with positive expression of p-AKT2 were significantly poorer than those with negative expression(20% vs 56%,(28.464±2.235) months vs(39.214±3.075) months,P<0.05),while there were no significant differences with regard to AKT2 expression.Conclsuion The positive expression of p-AKT2 in lung adenocarcinoma was higher than that in lung sqamous carcinomas.p-AKT2 may be a prognostic factor for non-small cell lung cancer.
出处
《四川大学学报（医学版）》
CAS
CSCD
北大核心
2010年第4期586-589,共4页
Journal of Sichuan University(Medical Sciences)
